Semaglutide Tablets Dose: How the Wegovy Pill Schedule Works

Step 1: Starting at 1.5 mg and why the pace is deliberate

Every course of Wegovy tablets begins at 1.5 mg daily. If you have been researching GLP-1 medicines, you may be puzzled by how small that figure looks compared with the 25 mg you will eventually reach. The reason is straightforward: your gut needs time to adjust to a drug that deliberately slows gastric emptying. Moving through doses too quickly is the single biggest driver of the nausea and vomiting that put people off treatment early. Spending a full month at 1.5 mg is not a delay; it is the thing that makes the rest of the schedule bearable.

The oral semaglutide dose for weight loss is absorbed very differently from the injected version. The tablet contains an absorption enhancer called SNAC, which temporarily adjusts the stomach lining to let semaglutide cross into the bloodstream. That chemistry only works when the stomach is empty, which is why the timing rule (empty stomach, plain water, 30 minutes clear before anything else) is not optional. Coffee, other medicines, even a sip of juice in those 30 minutes can meaningfully reduce how much drug you absorb. A prescriber will go through this at consultation; the full detail is in the patient information leaflet supplied with your medication.

For clinical context, the MHRA approved this schedule based on the OASIS 4 phase-3 trial, which found an average weight reduction of around 13.6% over 64 weeks compared with around 2.4% on placebo. Among participants who stayed fully adherent to treatment, average loss was closer to 17%. The NHS semaglutide medicines page covers the approved uses and safety profile at patient level.

Step 2: Moving to 4 mg and 9 mg, reading your own response

After at least one month on 1.5 mg, the schedule moves to 4 mg daily, then to 9 mg daily after a further month. Most people notice their appetite starting to shift meaningfully somewhere in this range, meals feel satisfying with less food, and the urge to snack between them fades. That response is individual; some notice it early, others not until they reach the higher steps.

Side effects are most common when a dose increases, typically easing within one to two weeks as the body adjusts. The pattern is predominantly gastrointestinal: nausea, loose stools, indigestion, constipation, or a combination. In the OASIS 4 trial, around 74% of participants on oral semaglutide reported a GI side effect at some point, compared with 42% on placebo, most were mild to moderate and did not lead to stopping treatment. Staying hydrated and keeping meals smaller and lower in fat during the first weeks of each new dose level helps considerably. If symptoms are more than mildly inconvenient, that is a conversation for your prescriber, not a reason to stop quietly.

People already established on the Wegovy 2.4 mg weekly injection may be able to move directly to the 25 mg tablet, bypassing the lower steps, but only following clinical review. For practical detail on how oral semaglutide dosing compares with the injected route, we have covered that in full separately.

Step 3: Reaching 25 mg, what maintenance actually means

The 25 mg daily tablet is the licensed maintenance dose. After at least one month at 9 mg, a prescriber will assess whether you are ready to move up, considering both tolerability and your treatment progress. Maintenance does not mean the medicine stops working; for most people it is where the sustained weight-loss effect is established and held over time.

It is worth being clear about one common point of confusion: the 3 mg, 7 mg and 14 mg tablet strengths you may have seen mentioned online are Rybelsus, a separate semaglutide product licensed for type 2 diabetes management, not for weight loss. The 3 mg semaglutide tablet is a Rybelsus diabetes dose and has no place in the Wegovy weight-loss schedule. The two products share an active ingredient but have different licensed indications, different approved strengths, and different approved populations. Mixing them up is easy given the number of search results that conflate them; the distinction matters clinically.

If you are weighing up which treatment format suits you, our guide to semaglutide tablet dosing for weight loss covers the licensed evidence in more detail, and our treatment overview sets out how oral and injected options compare more broadly. On cost, the Wegovy pill UK guide sets private prescription pricing in honest context, worth reading before you compare providers.

What makes the tablet schedule a clinical decision, not a self-directed one

It might seem straightforward to follow a four-step chart. In practice, decisions arise that need a prescriber: whether a side effect at 9 mg warrants pausing before moving to 25 mg, whether a patient on other daily medicines needs a timing plan for those 30 minutes, or whether someone who has missed several days should restart at a lower dose or continue.

Wegovy tablets are prescription-only. The MHRA's approval reflects both the efficacy evidence and the requirement for clinical oversight throughout. At nume, every consultation is personally reviewed by a GPhC-registered Independent Prescriber (the same day, on the same working day you apply) and clinical review continues before every repeat. There is no automated approval; a real clinician reads your answers. If you have questions about whether the tablet or injection suits your situation better, the FAQs page covers the most common ones, or you can reach us directly via the contact page.

The government's announcement of the MHRA approval, published on GOV.UK on 11 June 2026, confirms the UK was the first country in Europe to license an oral GLP-1 for weight management, a detail that reflects the pace of development in this area rather than anything to celebrate prematurely. The medicine still needs to be taken correctly, titrated carefully, and used alongside the diet and activity changes that the licence specifies. Ready to check whether you are eligible? Check your eligibility with our clinical team.